pancreatic cancer cells

[Life Science Alliance] Reseachers showed that non-autologous exosomes could encapsulate CRISPR/Cas9 plasmid DNA via commonly available transfection reagents and could be delivered to recipient cancer cells to induce targeted gene deletion.

[Journal of Proteome Research] The impact of DNAJA1 expression on pancreatic ductal adenocarcinoma progression remains unclear. The metabolic impacts of increased DNAJA1 expression were evaluated using a combination of untargeted metabolomics, stable isotope-resolved metabolomics, confocal microscopy, flow cytometry, and cell-based assays.

[Scientific Reports] Metformin combined with apigenin increased ROS levels dramatically and decreased cell viability in various cancer cells including AsPC-1 cells, with each drug used singly having a minimal effect.

[Biomaterials Science] Scientists constructed a hybrid nanoplatform by fusing Celastrol-Loaded PEGylated lipids with the DC2.4 cell membrane to achieve targeted treatment of Kras-mutant pancreatic cancer.

[International Journal of Biochemistry & Cell Biology] Researchers presented the first comprehensive search for potential non-polyamine based polyamine transport inhibitors that work in human pancreatic cancer cells in vitro.

[Auris Medical Holding Ltd.] Auris Medical Holding Ltd. announced the selection of mutant KRAS-driven colorectal cancer as the first therapeutic indication for its OligoPhore™ oligonucleotide delivery platform, based on outcomes from studies with OligoPhore™ enabled KRAS silencing, and a well-defined regulatory and development pathway.